Resource Summary Report

Generated by dkNET on Sep 2, 2026

OCI-Ly3

RRID:CVCL_8800
Type: Cell Line

Proper Citation

RRID:CVCL_8800

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_8800

Proper Citation: RRID:CVCL_8800

Description: Cell line OCI-Ly3 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma activated B-cell type

Defining Citation: PMID:3567358, PMID:8574164, PMID:10676951, PMID:11807979, PMID:15122589, PMID:18323416, PMID:19278952, PMID:20054396, PMID:20628145, PMID:20889926, PMID:21179087, PMID:22460905, PMID:23257783, PMID:23292937, PMID:23321251, PMID:23699601, PMID:25485619, PMID:26589293, PMID:28196595, PMID:29416618, PMID:29666304, PMID:30285677, PMID:30894373, PMID:31068700, PMID:31160637, PMID:31978347

Comments: Caution: A cell line, now termed GNE-587170 (Cellosaurus=CVCL_AT69), was mistakenly distributed by OCI to a number of groups under the designation OCI-Ly-3, the origin of that cell line is now known., Population: Caucasian., From: Ontario Cancer Institute (OCI); Toronto; Canada., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OCI-Ly3

Synonyms: OCI-LY3, OCI-ly3, OCI-LY-3, Oci-Ly-3, OCI-Ly 3, OCILY-3, OCI-Ly03, OCI Ly3, OCILY3, Ly3, LY3

Cross References: EFO:EFO_0006710, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioGRID_ORCS_Cell_line:745, BioSample:SAMN10988130, cancercelllines:CVCL_8800, Cell_Model_Passport:SIDM01778, ChEMBL-Cells:CHEMBL4523534, ChEMBL-Targets:CHEMBL4523565, Cosmic:1290019, Cosmic:1329094, Cosmic:1486584, Cosmic:1487544, Cosmic:1517647, Cosmic:1541901, Cosmic:1548654, Cosmic:1550337, Cosmic:1945198, Cosmic:2276329, Cosmic:2437309, DepMap:ACH-000158, DSMZ:ACC-761, DSMZCellDive:ACC-761, EGA:EGAS00001000610, ENCODE:ENCBS018GXW, ENCODE:ENCBS757GPD, GEO:GSM1963, GEO:GSM2023, GEO:GSM380133, GEO:GSM552451, GEO:GSM887472, GEO:GSM888552, GEO:GSM1035342, GEO:GSM1059799, GEO:GSM1374787, GEO:GSM1890025, GEO:GSM1890026, GEO:GSM1890027, GEO:GSM1890028, GEO:GSM3150251, IARC_TP53:26922, LiGeA:CCLE_060, Lonza:945, PharmacoDB:OCILY3_1189_2019, PRIDE:PXD012087, Progenetix:CVCL_8800, PubChem_Cell_line:CVCL_8800, Wikidata:Q54931773

ID: CVCL_8800

Record Creation Time: 20220427T221355+0000

Record Last Update: 20260829T235504+0000

Ratings and Alerts

No rating or validation information has been found for OCI-Ly3.

No alerts have been found for OCI-Ly3.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Zhao J, et al. (2026) Construction and experimental verification of a prognostic model based on tumor-infiltrating lymphocytes related genes (TILRGs) in diffuse large B-cell lymphoma. SLAS technology, 39, 100425.

Xu ZZ, et al. (2026) A nanosensor platform for cell gene transfection and single-cell nanovibration dynamic monitoring. Talanta, 303, 129486.

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

L????nd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. Blood

cancer discovery, 6(6), 580.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. Cell, 188(2), 331.

Qiao Q, et al. (2025) Metabolism-related ALDH1B1 acts as potential predictor and therapeutic target for primary gastrointestinal diffuse large B-cell lymphoma. Apoptosis : an international journal on programmed cell death, 30(5-6), 1482.

Eiken AP, et al. (2024) Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects. Cancer research communications, 4(5), 1328.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer cell, 42(5), 833.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. Blood cancer discovery, 5(6), 417.

Eken JA, et al. (2024) Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL. The Journal of experimental medicine, 221(5).

He MY, et al. (2024) GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. Leukemia, 38(10), 2210.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Scheich S, et al. (2023) Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. Cancer discovery, 13(8), 1862.

Venturutti L, et al. (2023) An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. Cancer discovery, 13(1), 216.

Yang X, et al. (2023) Potential role of the P2X7 receptor in the proliferation of human diffused large B-cell lymphoma. Purinergic signalling.

Roider T, et al. (2021) The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. International journal of cancer, 148(1), 150.

Dersh D, et al. (2021) Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. Immunity, 54(1), 116.

Sadras T, et al. (2021) Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. Molecular cell, 81(10), 2094.

Portelinha A, et al. (2021) ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. Cell reports. Medicine, 2(7), 100350.

Yan P, et al. (2020) Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone. Cell reports, 31(13), 107840.